ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis

Inclusion Criteria: * Patients with the following hematologic malignancies: * Acute myelogenous leukemia (AML): High-risk and intermediate-risk AML including: * Antecedent hematological disease (e.g., myelodysplasia (MDS)) * Treatment-related leukemia * Complete Remission (CR1) with poor or intermediate-risk cytogenetics or molecular markers (e.g. Flt 3 mutation, 11q23, del 5, del 7, complex cytogenetics) * CR2 or CR3 * Induction failure or 1st relapse with \< 10% blasts in the marrow * Acute lymphoblastic leukemia (ALL): * High-risk CR1 including: * Poor-risk cytogenetics (e.g., Philadelphia chromosome t(9;22)or 11q23 rearrangements) * Philadelphia chromosome-like ALL * Presence of minimal disease by flow cytometry after 2 or more cycles of chemotherapy * No CR within 4 weeks of initial treatment * Induction failure with \< 10% blasts in the marrow * CR2 or CR3 * Myelodysplastic syndromes (MDS), Intermediate, High or Very High Risk by the revised international prognostic scoring system or treatment related MDS. * Bi-phenotypic or mixed-phenotypic acute leukemia in: * CR. * Induction failure or 1st relapse with \< 10% blasts in the marrow. * Chronic Myelogenous Leukemia (CML) in second chronic phase after accelerated or blast crisis. * Chronic Myelomonocytic Leukemia (CMML) * Hodgkin's Lymphoma that is relapsed or refractory * Age \> or equal to 18 years, \< or equal to 70yrs * KPS \> or equal t…